IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization

EMERALD-1 is first global Phase III trial to show improved clinical outcome for systemic therapy in combination with TACE in this setting

...

Related Keywords

Kunlun ,Zhejiang ,China ,Spain ,Australia ,Canada ,United States ,Sweden ,Japan ,United Kingdom ,San Francisco ,California ,Taiwan ,Cambridge ,Cambridgeshire ,South Korea ,Korea ,America ,American ,Swedish ,Susan Galbraith ,Bruno Sangro ,Daiichi Sankyo ,National Cancer Institute ,World Health Organization ,Biosciences Inc ,Astrazeneca ,Merck Co Inc ,Liver Unit ,Universidad De Navarra ,Executive Vice President ,Response Rate ,Blinded Independent Central Review ,Fatal Immune Mediated Adverse ,Mediated Nephritis ,Stevens Johnson Syndrome ,Full Prescribing Information ,Medication Guide ,North America ,South America ,Harbour Biomed ,Investigator Initiated Trial ,Rare Diseases ,Cancer Res Clin ,Korean Nationwide Cancer ,Accessed January ,View All ,Cancer Fact ,Hepatocellular Carcinoma ,World Fact ,Markets ,